Caplin Point Laboratories surged to a fresh all‑time high

Caplin Point Laboratories surged to a fresh all‑time high today (1 Sept 2026), touching ₹2,703.45 after reporting strong Q2 FY26 results with net profit up 18% YoY to ₹154.45 crore. The stock outperformed the pharma sector by nearly 8 percentage points, reflecting strong investor confidence. 📊 Q2 FY26 Results (Quarter ended Sept 25, 2026) Total Revenue: ₹534.04 crore (↑10.5% YoY) Operating Profit: ₹170.77 crore (↑15.4% YoY) Net Profit (PAT): ₹154.45 crore (↑18.1% YoY) Operating Margin: 31.98% (robust, among the highest in sector) Diluted EPS: ₹20.25 (↑18.3% YoY) 📈 Stock Performance – 1 Sept 2026 NSE Price: ₹2,704 (↑7.41%) BSE Price: ₹2,682.85 (↑6.58%) Intraday High: ₹2,703.45 (new all‑time high) 52‑Week Range: ₹1,502.45 – ₹2,700.00 Volume: 1.55 million shares traded on NSE 🔎 Market Context Outperformance: Caplin Point rose 8.33% intraday, while Sensex gained only 0.26%. Sector Comparison: Pharma & Biotech peers lagged, making Caplin’s rally stock‑specific. Momentum: Two‑day winning streak with cumulative 7.23% gain. Long‑term returns: 1‑year: +28.75% vs Sensex ‑3.98% 3‑year: +145.78% vs Sensex +17.94% 5‑year: +269.34% vs Sensex +34.49% 10‑year: +1,034% ⚠️ Investor Watchpoints Valuation: Current P/E ~29× TTM earnings — reflects growth optimism but premium pricing. Resistance: ₹2,700 is a psychological barrier; sustaining above this level will confirm breakout. Support: ₹2,538 (20‑DMA) and ₹2,257 (100‑DMA). Risk: Any slowdown in export markets or regulatory hurdles could trigger profit‑booking.